Follow the Money, Expose the System, Demand Accountability | PBM Reform with APCI
- 52m
- Transcript
Summary
Written by a model from the transcript; not yet reviewed.
This episode explores the complex and opaque world of pharmaceutical benefit management, drug pricing mechanisms, and PBM reform. The guest and the host discuss a recent study analyzing drug cost comparisons utilizing Mark Cuban's cost-plus pharmacy model alongside national average drug acquisition costs, highlighting massive markups and potential employer savings. They explain how legacy PBMs use aggregate pricing, effective rates, and cross-subsidization to obscure actual drug costs, and emphasize the critical need for employers and regulators to demand complete data transparency.
- Employers should demand full data transparency and access to their claims data to properly understand prescription drug costs. 46:55
- Moving to mandatory reporting for benchmark pricing indices like NADAC can close transparency gaps across all distribution channels. 40:31
- Aligning financial incentives and eliminating cross-subsidization in the supply chain can right-size compensation for pharmacies. 44:34
Chapters
- 0:05Podcast Introduction and Host Overview
The hosts introduce the Pharmacy Podcast Network and set the stage for a deep dive into PBM reform.
- 3:10Antonio’s Background and Early Career in Pharmacy
Antonio recounts his upbringing in pharmacy, his shift away from the profession, and his eventual return to drug pricing analysis.
- 4:00Expansion of Spread Pricing Across States
The discussion moves to how Ohio’s findings spurred investigations in other states, revealing widespread spread pricing issues.
- 5:15Ohio Medicaid PBM Spread Pricing Investigation
Antonio explains how publicly available data uncovered $245 million in hidden PBM spread pricing in Ohio Medicaid.
- 8:31Three Axis Advisors and Data Analytics Approach
Antonio describes the founding of Three Axis Advisors and their bottom‑up data analytics methodology to expose pricing practices.
- 12:00Effective Rate Pricing and Aggregate Pricing Issues
Antonio explains how PBMs use effective rate pricing to mask spread pricing and the implications for transparency.
- 13:59Mark Cuban Cost‑Plus Drug Analysis and Savings
Antonio details a study comparing employer costs under legacy PBMs to those under Mark Cuban’s cost‑plus model, highlighting significant savings.
- 16:00Closing Reflections and Future of Drug Pricing Reform
The episode concludes with reflections on the need for more data-driven analysis and the promise of future reforms in drug pricing.
- 35:20NADAC as a Transparent Benchmark
The conversation turns to NADAC, its strengths, limitations, and potential as a mandatory reporting benchmark for drug pricing.
- 48:04Employer Strategies for Transparency and Data Access
The hosts advise employers on how to demand transparency, verify data, and navigate conflicts of interest in PBM contracts.
Highlights
- 5:23
Uncovering Ohio Medicaid Spread Pricingdata
The guest discusses how using publicly available data helped uncover $245 million of hidden PBM spread pricing in Ohio Medicaid.
- 18:40
Comparing generic drug claims showed that Cost Plus Drugs delivered 37% savings across all transactions compared to commercial PBMs.
- 26:14
Biosimilar Savings vs Gross Pricesdata
An analysis of employer claims showed that Mark Cuban Cost Plus Drugs could have saved employers 93% on drugs with biosimilar equivalents.
- 31:08
Effective Rate Pricing Shell Gameinsight
The discussion highlights how PBMs engage in aggregate and effective rate pricing to move money around rather than using claim-specific reimbursement.
- 36:19
Exploding Savings on Non-NADAC Drugsdata
Mark Cuban cost-plus savings explode to over $200 per claim on non-NADAC drugs, demonstrating severe markups outside the retail channel.
- 48:33
Price Discrimination by Major PBMsinsight
The guest explains that the same PBM can yield hundreds of different prices for the exact same drug across different clients.
Quotes
“Spread pricing, of course, being the difference between what a PBM pays a pharmacy for a prescription claim and then what they bill the plan sponsor for that same set of claims.”
Unnamed speaker · 5:33 “And so while pharmacists in Ohio were complaining about underpayments in the Medicaid program in Ohio, on the other end of the transaction, Ohio Medicaid was complaining about the cost of the transaction.”
Unnamed speaker · 4:47 “The beauty of NADAC is that no one company can screw it up.”
Unnamed speaker · 25:34 “If you want to pay for more, you want to pay for a specialty pharmacy service, you want to pay for a medication therapy management service.”
Unnamed speaker · 43:46 “First, distrust but verify. Get access to your data.”
Unnamed speaker · 48:04
About this episode
In this special edition of the PBM Reform Podcast, host Greg Reybold welcomes nationally recognized drug pricing expert Antonio Ciaccia for an unfiltered conversation about pharmacy benefit managers (PBMs), hidden financial incentives, and the growing movement toward meaningful reform. Ciaccia has spent years investigating the economics of prescription drug distribution, helping uncover hundreds of millions of dollars in questionable Medicaid drug spending and exposing the financial mechanisms behind inflated drug prices. His latest work with 3 Axis Advisors raises important questions about whether conventional PBM contracts deliver the savings they promise. An October 2026 analysis compares Mark Cuban Cost Plus Drug Company's published prices with traditional PBM pricing arrangements. Another June 2026 report examines how retrospective rebates, pricing benchmarks, and administrative arrangements create financial risks for employers and health plans. Ciaccia has also described three forces capable of driving PBM reform: legislation, litigation, and market-based competition. As he told Drug Topics, borrowing a familiar expression from Greg Reybold: “Pressure busts pipes.” In This Episode Why PBM pricing transparency remains essential for employers, patients, and pharmacies. What recent drug pricing research reveals about hidden costs and contractual complexity. How cost-plus pharmacy models challenge traditional PBM economics. Why independent pharmacies continue facing reimbursement and cash-flow pressures. Whether federal reform and marketplace competition can produce lasting accountability. How pharmacists, employers, and policymakers can demand measurable results. The future of pharmacy benefits depends on more than promises of reform. It demands transparency, accountability, and evidence that savings actually reach the people paying for healthcare. Join Greg Reybold and Antonio Ciaccia as they follow the money and examine what's next for PBM reform.
Transcript
8,630 words · 4 speakers
Topics
- NADAC
- PBM
- Ohio
- Mark Cuban Cost Plus Drugs
- Georgia
- Ohio Medicaid
- Three Axis Advisors
- Ohio Pharmacists Association
- APCI
- 46 Brooklyn Research
Page updated · transcript and summary are machine-generated